Valvano Antonio, Bosso Giorgio, Apuzzi Valentina, Riccone Filippo, Saccà Luigi, Oliviero Ugo
Department of Translational Medical Sciences, Federico II University, Naples 80131, Italy.
Department of Translational Medical Sciences, Federico II University, Naples 80131, Italy.
Atherosclerosis. 2015 Dec;243(2):407-13. doi: 10.1016/j.atherosclerosis.2015.10.007. Epub 2015 Oct 9.
The aim of this study was to evaluate the acute and chronic effects of mesoglycan on the endothelial function and arterial elastic properties in patients with metabolic syndrome (MetS).
MetS is defined by a clustering of vascular risk factors that demand both pharmacologic and non-pharmacologic interventions, including body weight reductions and physical activity. The correction of endothelial dysfunction and arterial wall distensibility associated with MetS have lately received increasing interest.
Thirty consecutive ambulatory patients affected by MetS were 2:1 randomized in a double-blind fashion to receive mesoglycan or placebo, respectively. In the first phase of the study, we evaluated the acute effects of a single i.m. administration of mesoglycan (60 mg) or placebo on vascular reactivity, as assessed by brachial flow-mediated dilation (FMD). Then, patients were chronically treated with mesoglycan per os (50 mg twice a day) or placebo for 90 days. At the end of this period, vascular reactivity and the arterial wall elastic properties were evaluated.
In the mesoglycan group, FMD increased above baseline after acute administration, with a maximum increment of 52% after 2 h. FMD was also significantly greater than baseline after 90 days of chronic treatment. In the placebo group, FMD was unaffected by both acute and chronic mesoglycan administration. Moreover, after 90 days of mesoglycan treatment, a marked improvement in arterial distensibility and compliance was detected and arterial stiffness reduced significantly.
This small, preliminary study shows that mesoglycan exerts relevant effects on vascular physiology, both in an acute setting as well as after prolonged, three-month treatment, in patients affected by metabolic syndrome.
本研究旨在评估硫酸软骨素对代谢综合征（MetS）患者内皮功能和动脉弹性特性的急性和慢性影响。
代谢综合征由一系列血管危险因素聚集而成，需要药物和非药物干预，包括减轻体重和进行体育活动。与代谢综合征相关的内皮功能障碍和动脉壁扩张性的纠正近来受到越来越多的关注。
30例连续门诊的代谢综合征患者按2:1随机分为两组，分别接受硫酸软骨素或安慰剂，采用双盲方式。在研究的第一阶段，我们评估单次肌内注射硫酸软骨素（60mg）或安慰剂对血管反应性的急性影响，通过肱动脉血流介导的血管舒张（FMD）进行评估。然后，患者口服硫酸软骨素（50mg，每日两次）或安慰剂进行为期90天的长期治疗。在此期间结束时，评估血管反应性和动脉壁弹性特性。
在硫酸软骨素组，急性给药后FMD高于基线水平，2小时后最大增幅为52%。长期治疗90天后，FMD也显著高于基线水平。在安慰剂组，FMD不受急性和长期硫酸软骨素给药的影响。此外，硫酸软骨素治疗90天后，动脉扩张性和顺应性有明显改善，动脉僵硬度显著降低。
这项小型初步研究表明，硫酸软骨素对代谢综合征患者的血管生理有显著影响，无论是在急性情况下还是在为期三个月的长期治疗后。
